Priavoid
PrivateLast Round
Grant
Oct 1, 2024
Total Funding Raised
$8.47M
Momentum Score
50 /100
Company Overview
Priavoid is a biopharmaceutical company developing a novel class of orally available all-D-peptide therapeutics to inhibit and reverse disease-specific protein aggregation in neurodegenerative disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Priavoid Comps
Public and private peers based on sector, stage, and business model.
Priavoid Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Oct 1, 2024 | ||||
| Series A | Feb 12, 2021 |
Priavoid Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Rainwater Charitable Foundation | Grant |
| Alzheimer's Association | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 20, 2026
Monthly visitors grew 282% MoM, from 65 to 248.
- Jan 16, 2025
Monthly visitors grew 333% MoM, from 199 to 861.
Priavoid Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Priavoid's valuation, stock price, and market status.
